Quantessence Capital’s Avanos Medical AVNS Stock Holding History

Quantessence Capital’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$116K	–	31
2025 Q3	$116K	Buy	+10,000	New	+$117K	0.04%	168

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quantessence Capital's AVNS Position: Q4 2025 in Review

Quantessence Capital sold out of Avanos Medical (AVNS) in Q4 2025, closing a stake of 10,000 shares — an estimated $116K sold.

Quantessence Capital first reported a position in AVNS in Q3 2025 and held it in 1 quarter. The position peaked at $116K in Q3 2025. 274 funds tracked by Wall St. Rank hold AVNS as of Q4 2025.

Quantessence Capital reported no remaining Avanos Medical position as of Q4 2025 after selling out during the quarter.
Quantessence Capital sold 10,000 Avanos Medical shares in Q4 2025, an estimated $116K.
Quantessence Capital first reported a position in Avanos Medical in Q3 2025 and held it in 1 quarter.
Quantessence Capital's Avanos Medical position peaked at $116K in Q3 2025.
274 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2025.

Based on Quantessence Capital's 13F filing for Q4 2025, filed 17 Feb 2026.